# Jean‐Charles Soria

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jean-charles-soria/

## Facts

| Field | Value |
| --- | --- |
| Citations | 92,192 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 130 |
| i10-index | 550 |
| OpenAlex ID | https://openalex.org/A5021624793 |
| ORCID iD | https://orcid.org/0000-0001-9597-0701 |
| Works | 1,606 |

## Researcher papers

Showing 12 of 22.

- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors](https://scholariq.org/papers/gut-microbiome-influences-efficacy-of-pd-1-based-immunotherapy-against/)
- [Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/)
- [Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-i-egfr-i-mutated-advanced-nsclc/)
- [Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer](https://scholariq.org/papers/integrative-genome-analyses-identify-key-somatic-driver-mutations-of-small-cell/)
- [First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study](https://scholariq.org/papers/first-line-ceritinib-versus-platinum-based-chemotherapy-in-advanced-alk/)
- [Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)](https://scholariq.org/papers/routine-molecular-profiling-of-patients-with-advanced-non-small-cell-lung-cancer/)
- [Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy](https://scholariq.org/papers/hyperprogressive-disease-in-patients-with-advanced-non-small-cell-lung-cancer/)
- [Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer](https://scholariq.org/papers/intestinal-akkermansia-muciniphila-predicts-clinical-response-to-pd-1-blockade/)
- [Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/rociletinib-in-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial](https://scholariq.org/papers/genomic-and-transcriptomic-profiling-expands-precision-cancer-medicine-the/)
- [Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial](https://scholariq.org/papers/gefitinib-plus-chemotherapy-versus-placebo-plus-chemotherapy-in-egfr-mutation/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.